PML

Wistar Research Identifies Mechanisms for Selective Multiple Sclerosis Treatment Strategy

Retrieved on: 
星期二, 五月 28, 2024
Wistar, EBV, PML, Bangladesh Technical Education Board, Phenotype, Nature Microbiology, Nervous system, Patient, Data collection, Wistar Institute, TAF, Sclerosis, Immune system, Travel, FOXP1, Disease, DSM-IV codes, Multiple sclerosis, Epstein–Barr virus infection, SLCL, Liebermann, Neuron, Collaborative writing, Gene, Immortalised cell line, Cell, Manuscript, IL-6, Brain, Inflammation, R01, Vaccine

Though researchers know that EBV can contribute to the development of MS, the exact mechanisms by which it does so aren’t completely understood.

Key Points: 
  • Though researchers know that EBV can contribute to the development of MS, the exact mechanisms by which it does so aren’t completely understood.
  • As a whole, the group’s findings suggested a mechanism of lytic EBV in MS that promoted inflammation and disease.
  • TAF also significantly reduced the expression of inflammatory cytokines like IL-6 in the SLCLs from the patients with active MS.
  • The funders had no role in study design; data collection and analysis; decision to publish; or preparation of the manuscript.

Prime Matter Labs Unveils Element, Its Proprietary Cloud-Based Product Development Platform

Retrieved on: 
星期二, 三月 5, 2024
ERP, Acquisition, AI, PML, Life, Feedback, Prime, Plague, Beauty, Video game

NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Prime Matter Labs (PML), a leading contract manufacturer of beauty and personal care products, today announced the launch of its new customer-facing, proprietary, cloud-based platform, Element by Prime Matter Labs.

Key Points: 
  • NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Prime Matter Labs (PML), a leading contract manufacturer of beauty and personal care products, today announced the launch of its new customer-facing, proprietary, cloud-based platform, Element by Prime Matter Labs.
  • Element is a fully integrated platform that leverages industry-leading technology and AI functionality to help make the entire product development and production process more intuitive and effective for customers.
  • Element is the first-of-its-kind software platform that acts as the backbone of a brand's product development and production process from concept to creation to completion in one centralized location.
  • “With the launch of Element, Prime Matter Labs is the first contract manufacturer to provide native technology capable of connecting high-growth brands directly to their product development and manufacturing process,” said Adam Price, VP of Software and Technology at Prime Matter Labs.

Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Retrieved on: 
星期五, 一月 5, 2024
Urine, Medical Subject Headings, Diarrhea, Marketing, INN, Risk, Immune system, Stomach, Multiple sclerosis, ATC, Pain, Capsule, International, Spinal cord, Disease, PML, Nausea, Language, Brain, Mouth, Eye, Inflammation, Flushing, Antioxidant, European Medicines Agency, Gene, Glatiramer acetate, Select, Central nervous system, Patient, Cell, Safety, Encephalitis, Anatomy, IIA, Optic nerve, Skin, Medical device

Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Vumerity, diroximel fumarate, Date of authorisation: 15/11/2021, Revision: 5, Status: Authorised

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Retrieved on: 
星期四, 一月 4, 2024
Marketing, BAL, PV, INN, Risk, MPA, Shivering, DLBCL, CD20, BLL, PML, Pemphigus vulgaris, Cancer, Inflammation, Infection, Anatomy, IIA, Skin, Chills, Fever, ATC, Joint, Bone marrow, GPA, Disease, Nose, Ageing, Allergy, Glucocorticoid, CLL, NHL, Safety, Rheumatoid arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Granuloma, Antibody, Vincristine, International, Arthritis, Language, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, Overview, B cell, Methotrexate, Prednisolone, TNF, CHOP, Blood, Vasculitis, Lymphocytosis, European Medicines Agency, Doxorubicin, Chronic lymphocytic leukemia, DMARD, Medical device

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Urine, Medical Subject Headings, Diarrhea, Marketing, INN, Risk, Immune system, Stomach, Interferon beta-1a, ATC, Pain, Multiple sclerosis, Capsule, International, RRMS, Spinal cord, Disease, PML, Ageing, Nausea, Language, Brain, Mouth, Eye, Inflammation, Flushing, European Medicines Agency, Food, Gene, Glatiramer acetate, Select, Central nervous system, Patient, Safety, Encephalitis, Anatomy, Sclerosis, Optic nerve, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Tecfidera, dimethyl fumarate, Date of authorisation: 30/01/2014, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 20, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, INN, Risk, MPA, Shivering, CD20, PML, ACR20, Pemphigus vulgaris, Cancer, Inflammation, Death, Infection, Anatomy, IIA, Skin, Chills, Fever, ATC, Bone marrow, GPA, Disease, Allergy, Hepatitis B virus, CLL, NHL, Safety, Arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Antibody, Vincristine, International, Language, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, Encephalitis, Medicine, B cell, Prednisolone, Autoimmune disease, CHOP, Blood, Rheumatoid arthritis, Vasculitis, European Medicines Agency, Doxorubicin, Cell, Chronic lymphocytic leukemia, Resuscitation, Medical device

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 20, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, INN, Risk, MPA, Shivering, CD20, PML, ACR20, Pemphigus vulgaris, Cancer, Inflammation, Death, Infection, Anatomy, IIA, Skin, Chills, Fever, ATC, Joint, Bone marrow, GPA, Disease, Pemphigus, Allergy, B cell, Hepatitis B virus, Glucocorticoid, NHL, CLL, Safety, Rheumatoid arthritis, Arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Granuloma, Antibody, Vincristine, International, Language, Blood, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, Methotrexate, Prednisolone, Autoimmune disease, TNF, CHOP, Vasculitis, European Medicines Agency, Doxorubicin, Cell, Chronic lymphocytic leukemia, Resuscitation, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 12, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, PV, INN, Risk, MPA, Shivering, CD20, PML, Pemphigus vulgaris, Inflammation, Infection, Anatomy, Lymphoma, IIA, Skin, Chills, Fever, ATC, Joint, Bone marrow, GPA, Disease, Nose, Allergy, Glucocorticoid, NHL, CLL, Safety, Rheumatoid arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Granuloma, Antibody, Vincristine, International, Arthritis, Language, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, B cell, Methotrexate, Prednisolone, TNF, CHOP, Blood, Vasculitis, European Medicines Agency, Doxorubicin, Chronic lymphocytic leukemia, DMARD, Medical device

Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 12, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Patient, Medical Subject Headings, Marketing, MRI, INN, Risk, Interferon beta-1a, Immune system, Fatigue, Infection, Registry, ATC, Antibody, Gadolinium, Disability, Multiple sclerosis, International, Attack, Spinal cord, Disease, Common, PML, Nose, Headache, Nausea, Brain, Language, Urinary tract infection, Inflammation, Cancer, Nerve, Dizziness, Skin cancer, Allergy, DMT, Death, European Medicines Agency, Nervous system, Select, Carcinoma, Safety, Encephalitis, Anatomy, Arthralgia, Sclerosis, IIA, Magnetic resonance imaging, Medical device

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 42, Status: Authorised

Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 15, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, BAL, PV, INN, Risk, MPA, Shivering, DLBCL, Pemphigus, CD20, BLL, PML, Pemphigus vulgaris, Cancer, Inflammation, Infection, Anatomy, IIA, Skin, Chills, Fever, ATC, Bone marrow, GPA, Nose, Ageing, Allergy, Glucocorticoid, CLL, NHL, Safety, Rheumatoid arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Granuloma, Antibody, Vincristine, International, Arthritis, Language, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, Methotrexate, Prednisolone, TNF, CHOP, Blood, Vasculitis, Lymphocytosis, European Medicines Agency, Doxorubicin, Chronic lymphocytic leukemia, DMARD, Medical device

Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 15, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Riximyo, rituximab, Date of authorisation: 15/06/2017, Revision: 15, Status: Authorised